Galapagos increases share capital through subscription right exercises
04 Dicembre 2020 - 10:01PM
Mechelen, Belgium; 4 December 2020, 22.01
CET; regulated information – Galapagos NV (Euronext & NASDAQ:
GLPG) announces a share capital increase arising from subscription
right exercises.
Galapagos issued 70,925 new ordinary shares on 4
December 2020, for a total capital increase (including issuance
premium) of €2,615,857.50.
Pursuant to the subscription right exercise
program of Galapagos’ management board, members of the management
board automatically are committed to exercise a minimum number of
subscription rights, subject to certain conditions. In accordance
with the rules of this program, CEO Onno van de Stolpe exercised
15,000 subscription rights. Three other management board members
exercised an aggregate number of 15,000 subscription rights.
In accordance with Belgian transparency
legislation1, Galapagos notes that its total share capital
currently amounts to €353,819,443.97, the total number of
securities conferring voting rights amounts to 65,411,767, which is
also the total number of voting rights (the “denominator”), and all
securities conferring voting rights and all voting rights are of
the same category. The total number of rights (formerly known as
warrants) to subscribe to not yet issued securities conferring
voting rights is (i) 6,928,337 subscription rights under several
outstanding employee subscription right plans, which equals
6,928,337 voting rights that may result from the exercise of those
subscription rights, and (ii) one subscription right issued to
Gilead Therapeutics to subscribe for a maximum number of shares
that is sufficient to bring the shareholding of Gilead and its
affiliates to 29.9% of the actually issued and outstanding shares
after the exercise of the subscription right. Galapagos does not
have any convertible bonds or shares without voting rights
outstanding.
About GalapagosGalapagos
(Euronext & NASDAQ: GLPG) discovers and develops small molecule
medicines with novel modes of action, several of which show
promising patient results and are currently in late-stage
development in multiple diseases. Our pipeline comprises Phase 3
through to discovery programs in inflammation, fibrosis, and other
indications. Our ambition is to become a leading global
biopharmaceutical company focused on the discovery, development and
commercialization of innovative medicines. More information at
www.glpg.com.
Contacts
Investors:Elizabeth GoodwinVP Investor
Relations +1 781 460 1784
Sofie Van GijselSenior Director Investor Relations+32 485 19 14
15ir@glpg.com
Media:Carmen VroonenGlobal Head of
Communications & Public Affairs+32 473 824 874
Anna GibbinsSenior Director Therapy Areas Communications +44
7717 801900 communications@glpg.com
Forward-looking statements
This release may contain forward-looking
statements. Such forward-looking statements are not guarantees of
future results. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any forward-looking statements
in this document, unless specifically required by law or
regulation.
1 Belgian Act of 2 May 2007 on the disclosure
of major shareholdings in issuers whose shares are admitted to
trading on a regulated market
- Galapagos increases share capital through subscription right
exercises
Grafico Azioni Galapagos (EU:GLPG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Galapagos (EU:GLPG)
Storico
Da Apr 2023 a Apr 2024
